London
· Delayed Price · Currency is GBP · Price in GBXBeximco Pharmaceuticals Statistics
Total Valuation
Beximco Pharmaceuticals has a market cap or net worth of GBP 215.61 million. The enterprise value is 277.46 million.
| Market Cap | 215.61M |
| Enterprise Value | 277.46M |
Important Dates
The next estimated earnings date is Monday, November 4, 2024.
| Earnings Date | Nov 4, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 297.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.31 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.53, with an EV/FCF ratio of 6.09.
| EV / Earnings | 7.24 |
| EV / Sales | 1.00 |
| EV / EBITDA | 4.53 |
| EV / EBIT | 5.57 |
| EV / FCF | 6.09 |
Financial Position
The company has a current ratio of 1.80, with a Debt / Equity ratio of 14.73.
| Current Ratio | 1.80 |
| Quick Ratio | 0.45 |
| Debt / Equity | 14.73 |
| Debt / EBITDA | 0.78 |
| Debt / FCF | 1.17 |
| Interest Coverage | 6.82 |
Financial Efficiency
Return on equity (ROE) is 10.99% and return on invested capital (ROIC) is 8.37%.
| Return on Equity (ROE) | 10.99% |
| Return on Assets (ROA) | 6.97% |
| Return on Capital (ROIC) | 8.37% |
| Revenue Per Employee | 54,353 |
| Profits Per Employee | 6,725 |
| Employee Count | 5,700 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 1.77 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -43.20% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -43.20% |
| 50-Day Moving Average | 33.75 |
| 200-Day Moving Average | 37.75 |
| Relative Strength Index (RSI) | 15.19 |
| Average Volume (20 Days) | 417,779 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Beximco Pharmaceuticals had revenue of GBP 309.81 million and earned 38.33 million in profits. Earnings per share was 0.09.
| Revenue | 309.81M |
| Gross Profit | 133.95M |
| Operating Income | 55.76M |
| Pretax Income | 49.78M |
| Net Income | 38.33M |
| EBITDA | 67.87M |
| EBIT | 55.76M |
| Earnings Per Share (EPS) | 0.09 |
Balance Sheet
The company has 12.45 million in cash and 53.41 million in debt, giving a net cash position of -40.96 million.
| Cash & Cash Equivalents | 12.45M |
| Total Debt | 53.41M |
| Net Cash | -40.96M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 362.49M |
| Book Value Per Share | 0.75 |
| Working Capital | 69.55M |
Cash Flow
In the last 12 months, operating cash flow was 60.21 million and capital expenditures -14.64 million, giving a free cash flow of 45.57 million.
| Operating Cash Flow | 60.21M |
| Capital Expenditures | -14.64M |
| Free Cash Flow | 45.57M |
| FCF Per Share | n/a |
Margins
Gross margin is 43.24%, with operating and profit margins of 18.00% and 12.37%.
| Gross Margin | 43.24% |
| Operating Margin | 18.00% |
| Pretax Margin | 16.07% |
| Profit Margin | 12.37% |
| EBITDA Margin | 21.91% |
| EBIT Margin | 18.00% |
| FCF Margin | 14.71% |
Dividends & Yields
Beximco Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | -7.55% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 29.69% |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 39.96% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on November 23, 2020. It was a forward split with a ratio of 1.1.
| Last Split Date | Nov 23, 2020 |
| Split Type | Forward |
| Split Ratio | 1.1 |